Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Jiangsu Hengrui Medicine

    Client Virtual Booth

    JIANGSU HENGRUI MEDICINE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Jiangsu Hengrui Medicine
    China Flag
    Country
    Country
    China
    Address
    Address
    No.7 Kunlunshan Road, Lianyungang Eco & Tech Development Zone, Lianyungang, Jiangsu Province 222047
    Telephone
    Telephone
    +86 518 81220983
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hengrui.com/en/about.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/jiangsu-hengrui-pharmaceuticals/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab

    https://www.globenewswire.com//news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share
    Mycovia Announces Partner Jiangsu Hengrui's Approval of Oteseconazole Capsules
    Mycovia Announces Partner Jiangsu Hengrui's Approval of Oteseconazole Capsules

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-approval-of-oteseconazole-capsules-for-the-treatment-of-severe-vulvovaginal-candidiasis-vvc-in-china-301904626.html

    PR NEWSWIRE
    21 Aug 2023
    Share Share
    Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR
    Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR

    https://www.hengrui.com/en/media/detail-320.html

    PRESS RELEASE
    10 Apr 2023
    Share Share
    Camrelizumab with Rivoceranib vs. Sorafenib, a Joint Program with Elevar
    Camrelizumab with Rivoceranib vs. Sorafenib, a Joint Program with Elevar

    https://www.prnewswire.com/news-releases/camrelizumab-in-combination-with-rivoceranib-apatinib-significantly-prolonged-overall-survival-and-progression-free-survival-vs-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma-in-a-multinational-phase-3-trial--301621486.html

    PRNEWSWIRE
    11 Sep 2022
    Share Share
    Camrelizumab in Combo with Rivoceranib Significantly Prolonged Overall Survival
    Camrelizumab in Combo with Rivoceranib Significantly Prolonged Overall Survival

    https://www.hengrui.com/en/media/detail-254.html

    PRESS RELEASE
    10 Sep 2022
    Share Share
    Dalpiciclib in Combo with Letrozole or Anastrozole Significantly Progression
    Dalpiciclib in Combo with Letrozole or Anastrozole Significantly Progression

    https://www.hengrui.com/en/media/detail-252.html

    PRESS RELEASE
    29 Aug 2022
    Share Share
    Chinese pharma giant Hengrui launches new company for globalization play
    Chinese pharma giant Hengrui launches new company for globalization play

    https://endpts.com/chinese-pharma-giant-hengrui-launches-new-company-for-globalization-play-with-a-merck-kgaa-vet-at-the-helm/

    T. Patchen ENDPTS
    19 May 2022
    Share Share
    Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m
    Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m

    https://scrip.pharmaintelligence.informa.com/SC146406/Small-Molecules-Attract-Investors-As-Two-Chinese-Biotechs-Bag-$161m

    Dexter Yan SCRIP
    19 May 2022
    Share Share
    Hengrui Pharma Announces Frontline Camrelizumab in Combination with Rivoceranib
    Hengrui Pharma Announces Frontline Camrelizumab in Combination with Rivoceranib

    https://www.hengrui.com/en/media/detail-244.html

    PRESS RELEASE
    13 May 2022
    Share Share
    Another Chinese PD-1 cancer med eyes FDA filing in liver cancer
    Another Chinese PD-1 cancer med eyes FDA filing in liver cancer

    https://www.fiercepharma.com/pharma/another-chinese-pd-1-immunotherapy-eyes-fda-application-hengrui-touts-win-liver-cancer

    Angus Liu FIERCEPHARMA
    12 May 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search